Evidence map›Paper›PMID 41175280›Full record

ArticleObesity surgery2025

Association Between Sugammadex Use and Risk of Postoperative Urinary Complications after Metabolic and Bariatric Surgery: A Multi-Institutional Study.

Ching-Chung Ko, Li-Chen Chang, Kuo-Chuan Hung, Yi-Chen Lai, Jheng-Yan Wu, Fu-Chi Kang

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Obesity surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ching-Chung Ko *Department of Medical Imaging, Chi Mei Medical Center, Tainan City, Taiwan.
Li-Chen ChangDepartment of Anesthesiology, E-Da Hospital, I-Shou University, Kaohsiung City, Taiwan.
Kuo-Chuan Hung *Department of Anesthesiology, Chi Mei Medical Center, Tainan City, Taiwan.
Yi-Chen LaiDepartment of Anesthesiology, Chi Mei Medical Center, Tainan City, Taiwan.
Jheng-Yan WuDepartment of Nutrition, Chi Mei Medical Center, Tainan City, Taiwan.
Fu-Chi KangDepartment of Anesthesiology, Chi Mei Medical Center, Chiali, Tainan City, Taiwan. kangfuchi321@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPostoperative urinary retention (POUR) is a common complication of metabolic and bariatric surgery (MBS) and is potentially exacerbated by neostigmine reversal and its required anticholinergic agents. This multi-institutional study aimed to evaluate the association between sugammadex use and postoperative urinary tract complications in this surgical population.

methodsThis retrospective cohort study analyzed TriNetX Research Network data from adult patients undergoing laparoscopic MBS (2015-2024). Patients receiving sugammadex were compared with those receiving neostigmine with glycopyrrolate/atropine using propensity score matching. Outcomes of interest included risks of POUR (primary outcome), urinary tract infection, cystitis, and Foley catheter insertion within 30 days postoperatively.

resultsAfter propensity score matching, 31,692 patients were analyzed. At the 30-day follow-up, sugammadex use was associated with a lower risk of POUR (odds ratio [OR] 0.20, 95% confidence interval [CI] 0.15-0.26, p < 0.001) and Foley catheter insertion (OR 0.38, 95% CI 0.26-0.55, p < 0.001), without differences in other outcomes. Temporal analysis showed that sugammadex conferred the greatest protection against POUR (OR 0.19, p < 0.001) and catheter insertion (OR 0.36, p < 0.001) during the early postoperative period (0-7 days), with no significant differences observed in other outcomes. In the late period (8-30 days), sugammadex use was associated with a delayed reduction in urinary tract infections (OR 0.67, 95% CI 0.48-0.94, p = 0.019), without differences in other outcomes.

conclusionSugammadex use is associated with significantly reduced postoperative urinary complications following MBS, offering important clinical advantages over traditional neuromuscular blockade reversal.

Indexed as

Bariatric SurgeryPostoperative ComplicationsSugammadexUrinary RetentionAdultFemaleHumansMaleMiddle AgedNeostigminePropensity ScoreRetrospective StudiesUrinary Tract InfectionsNeostigmineSugammadexBariatric surgeryNeuromuscular blockade reversalPostoperative urinary retentionPropensity score matchingSugammadexUrinary tract infection

Identifiers

PMID41175280

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.